Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

BARDA supports new broad-spectrum antibiotic to treat anthrax, tularmia

Date: May 24, 2013 

Company: Cempra Pharmaceuticals of Chapel Hill, N.C.

Contract amount: $17.7 million for two years

About the contract: The contract supports studies needed to request FDA approval of a drug called solithromycin to treat adults and children infected with anthrax, tularemia or community-acquired bacterial pneumonia. If approved, the drug would be the first orally administrated antibiotic approved in decades to treat children who develop community acquired bacterial pneumonia. Studies of the drug’s use in treating anthrax or tularemia will be conducted under the FDA’s Animal Efficacy Rule.

Additional information:  BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through a Broad Agency Announcement BARDA-BAA-12-100-SOL-00011at

Press Release: HHS funds drug development for bioterror infections

PHE Newsroom

Submit an Inquiry

Watch, Listen, Subscribe

Twitter  LinkedIn  Facebook  Instagram

Watch us on YouTube  Follow us on Flickr  Subcribe to our RSS  Subscribe to our email list

  • This page last reviewed: August 05, 2020